UBS’s AstraZeneca AZN Stock Holding History

UBS’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$143K	Buy	2,000 +400	+25%	+$29.3K	﹤0.01%	5549
2014 Q2	$119K	Sell	1,600 -2,000	-56%	-$145K	﹤0.01%	5732
2014 Q1	$234K	Sell	3,600 -1,700	-32%	-$110K	﹤0.01%	5016
2013 Q4	$315K	Sell	5,300 -81,700	-94%	-$4.44M	﹤0.01%	4801
2013 Q3	$4.52M	Buy	87,000 +14,300	+20%	+$718K	﹤0.01%	1796
2013 Q2	$3.44M	Buy	+72,700	New	+$3.7M	﹤0.01%	1972

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

UBS's AZN Position: Q3 2014 in Review

UBS reduced its AstraZeneca (AZN) stake by 2.7% in Q3 2014, selling an estimated $3.49M and leaving 1,725,695 shares worth $123M. The position accounts for 0.09% of the portfolio, ranked #231.

UBS first reported a position in AZN in Q2 2013 and has held it in 6 quarters since. The position peaked at $295M in Q3 2013. 401 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

UBS held 1,725,695 shares of AstraZeneca worth $123M as of Q3 2014.
UBS sold 47,642 AstraZeneca shares in Q3 2014, an estimated $3.49M.
AstraZeneca made up 0.09% of UBS's portfolio in Q3 2014, its #231 holding.
UBS first reported a position in AstraZeneca in Q2 2013 and has held it in 6 quarters since.
UBS's AstraZeneca position peaked at $295M in Q3 2013.
401 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.